Trial Profile
A retrospective study of CHEMOSAT in patients with non-resectable hepatic metastases from uveal melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 04 Nov 2015 New trial record
- 02 Nov 2015 Results published in Delcath System media release.
- 02 Nov 2015 Results presented at Delcath Systems media release.